![]() |
市場調查報告書
商品編碼
1954584
全球經直腸超音波市場:市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析及預測(2026-2034年)Transrectal Ultrasound Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
2025年全球經直腸超音波市場規模為 2.7111億美元,預計將從2026年的2.8797億美元成長至2034年的4.8964億美元,預測期內(2026-2034年)年複合成長率(CAGR)為 6.90%。北美地區將在2025年以 29.10%的市場佔有率引領市場,這主要歸功於該地區前列腺癌的高發病率、先進的醫療基礎設施以及有利的醫保償付政策。
經直腸超音波檢查(TRUS),也稱為直腸超音波或攝護腺超音波,是一種微創影像技術,主要用於診斷攝護腺癌、良性攝護腺增生(BPH)和攝護腺炎。此檢查需要將探頭插入直腸,並利用聲波產生前列腺的詳細影像。 TRUS 在前列腺癌篩檢、活檢引導和影像引導治療中發揮著非常重要的作用。
新冠疫情的影響
2020年,由於泌尿科手術減少和擇期手術推遲,新冠疫情對市場造成了重大影響。由於許多醫療系統優先治療新冠患者,前列腺癌篩檢和診斷影像被推遲。然而,從2020年第四季到2021年第一季,擇期手術逐漸恢復,市場需求趨於穩定。從2022年起,預計市場將穩定復甦,並持續成長至2034年。
市場概覽及關鍵指標
市場趨勢
先進影像與人工智慧整合系統的應用
領先企業加速推出具有增強成像功能的創新超音波平台。磁振造影-超音波融合活檢、高解析度微超音波和即時彈性成像等技術改變前列腺癌的診斷方式。
例如,ExactVu 微超音波平台採用 29MHz 的頻率,可實現前列腺組織的精細可視化。2023年 4月,EDAP TMS 的ExactVu 微超音波活檢系統在日本獲得銷售許可。此外,基於人工智慧的影像分析工具的開發也進行中,以提高診斷準確性。2023年發表的研究強調了人工智慧在經直腸超音波(TRUS)影像輔助前列腺癌鑑別診斷、改善活檢引導和提升診斷效果方面日益重要的作用。 市場成長因素
攝護腺癌發生率呈上升趨勢
攝護腺癌是全球男性最常見的癌症之一。根據世界癌症研究基金會(WCRF International)的資料,攝護腺癌是男性第二大常見癌症,2020年全球報告的新病例超過 140萬例。過去20年發病率的上升顯著增加了對早期檢測和診斷影像技術(例如經直腸超音波檢查(TRUS))的需求。
強而有力的償付政策和政府主導的措施
支持性的償付框架和宣傳活動促進早期診斷。諸如前列腺癌篩檢資助計畫和宣傳活動等措施推動先進診斷技術的應用。專注於超音波檢查償付策略的會議和政策舉措進一步鞏固了市場格局。
限制因子
儘管技術不斷進步,市場仍面臨產品召回和監管等挑戰。例如,近年來某些超音波系統的召回影響了其普及率。此外,訓練有素的技術人員和泌尿科醫生短缺,尤其是在已開發國家,可能會限制檢查能力。嚴格的監管要求也增加了製造商的合規成本。
市場區隔分析
依產品劃分
市場依產品分為系統與感測器兩大類。
依類型
市場分為推車式/手推車式系統和便攜式系統。
依應用
市場依應用分為診斷與影像導引治療。
依最終使用者劃分
市場細分為醫院和門診手術中心(ASC)、診斷實驗室和其他機構。
區域洞察
北美
北美市場規模到2025年達到 7,889萬美元,憑藉其較高的前列腺癌發病率和完善的醫療保健基礎設施,北美將繼續保持其主要市場地位。提高公眾意識和加強篩檢推廣工作推動進一步成長。
歐洲
在歐洲,預計年複合成長率將顯著提高,這得益於政府為促進前列腺癌早期檢測而採取的舉措以及先進活檢解決方案的監管審批。
亞太地區
由於醫療基礎設施的不斷完善、老舊超音波系統的升級以及中國、印度和日本等國家醫療支出的增加,亞太地區預計將實現強勁成長。
拉丁美洲、中東和非洲
由於認知度較低和醫療支出不足,這些地區的年複合成長率預計相對較低,但診斷的可及性預計將逐步提高。
主要公司
市場上主要的公司包括:
這些公司致力於收購、產品創新和獲得監管部門批准,以增強其競爭力。
產業主要動態
The global transrectal ultrasound market size was valued at USD 271.11 million in 2025 and is projected to grow from USD 287.97 million in 2026 to USD 489.64 million by 2034, registering a CAGR of 6.90% during the forecast period (2026-2034). North America dominated the market with a 29.10% share in 2025, driven by a high prevalence of prostate cancer, advanced healthcare infrastructure, and favorable reimbursement policies.
Transrectal ultrasound (TRUS), also known as endorectal ultrasound or prostate sonogram, is a minimally invasive imaging technique used primarily for diagnosing prostate-related conditions such as prostate cancer, benign prostatic hyperplasia (BPH), and prostatitis. The procedure involves inserting a probe into the rectum to produce detailed images of the prostate using sound waves. TRUS plays a crucial role in prostate cancer screening, biopsy guidance, and image-guided therapies.
COVID-19 IMPACT
The COVID-19 pandemic significantly affected the market in 2020 due to a decline in urological procedures and postponement of elective surgeries. Several healthcare systems prioritized COVID-19 patients, leading to delays in prostate cancer screenings and diagnostic imaging. However, between Q4 2020 and Q1 2021, elective procedures gradually resumed, stabilizing market demand. From 2022 onwards, the market witnessed steady recovery, and growth is expected to continue through 2034.
MARKET OVERVIEW & KEY METRICS
MARKET TRENDS
Launch of Advanced Imaging and AI-Integrated Systems
Leading companies are increasingly launching innovative ultrasound platforms with enhanced imaging capabilities. Technologies such as MRI-US fusion biopsy, high-resolution micro-ultrasound, and real-time elastography are transforming prostate cancer diagnostics.
For example, the ExactVu micro-ultrasound platform uses a 29 MHz frequency to provide detailed visualization of prostate tissues. In April 2023, EDAP TMS received regulatory approval in Japan to commercialize its ExactVu micro-ultrasound biopsy system. Additionally, AI-based imaging tools are being developed to improve diagnostic precision. Studies published in 2023 highlight the growing role of artificial intelligence in differentiating prostate cancer using TRUS images, improving biopsy guidance and diagnostic outcomes.
MARKET GROWTH FACTORS
Increasing Prevalence of Prostate Cancer
Prostate cancer is one of the most common cancers among men globally. According to the World Cancer Research Fund International, prostate cancer is the second most frequently occurring cancer in men, with over 1.4 million new cases reported worldwide in 2020. Rising incidence rates over the past two decades have significantly increased the demand for early detection and diagnostic imaging technologies such as TRUS.
Strong Reimbursement Policies and Government Initiatives
Supportive reimbursement frameworks and awareness programs are encouraging early diagnosis. Initiatives such as funding programs for prostate cancer research and screening awareness campaigns are promoting the adoption of advanced diagnostic technologies. Conferences and policy initiatives focusing on ultrasound reimbursement strategies have further strengthened the market landscape.
RESTRAINING FACTORS
Despite technological advancements, the market faces challenges including product recalls and regulatory scrutiny. For instance, recalls of certain ultrasound systems in previous years have affected adoption rates. Additionally, a shortage of trained technicians and urologists, particularly in developed countries, may limit procedural capacity. Stringent regulatory requirements also increase compliance costs for manufacturers.
MARKET SEGMENTATION ANALYSIS
By Product
The market is segmented into systems and transducers.
By Type
The market is divided into cart/trolley-based and portable systems.
By Application
The market is segmented into diagnostic and image-guided treatment.
By End-User
The market is categorized into hospitals & ASCs, diagnostic laboratories, and others.
REGIONAL INSIGHTS
North America
North America generated USD 78.89 million in 2025 and remained the leading region due to high prostate cancer prevalence and strong healthcare infrastructure. Increased awareness and screening initiatives are further driving growth.
Europe
Europe is projected to record a significant CAGR, supported by government initiatives promoting early prostate cancer detection and regulatory approvals for advanced biopsy solutions.
Asia Pacific
Asia Pacific is expected to witness strong growth due to expanding healthcare infrastructure, replacement of outdated ultrasound systems, and increasing healthcare expenditure in countries such as China, India, and Japan.
Latin America & Middle East & Africa
These regions are anticipated to grow at a comparatively lower CAGR due to limited awareness and lower healthcare spending, though gradual improvements in diagnostic access are expected.
KEY INDUSTRY PLAYERS
Major companies operating in the market include:
These players focus on acquisitions, product innovation, and regulatory approvals to strengthen their competitive position.
KEY INDUSTRY DEVELOPMENTS
CONCLUSION
The global transrectal ultrasound market is projected to grow from USD 271.11 million in 2025 to USD 489.64 million by 2034, expanding at a CAGR of 6.90%. The market is expected to reach USD 287.97 million in 2026, supported by increasing prostate cancer prevalence, advancements in AI-integrated imaging systems, and favorable reimbursement policies. Although challenges such as regulatory scrutiny and technician shortages persist, continuous technological innovation and growing awareness of early cancer detection are expected to sustain long-term market growth through 2034.
Segmentation By Product
By Type
By Application
By End-user
By Region